DD
MM
YYYY

PAGES

DD
MM
YYYY

spot_img

PAGES

Home Blog Page 14

U.S. Stocks Rebound Modestly as Chip Sector Leads Recovery and Middle East Tensions Ease Slightly

0

U.S. stocks ended mostly higher on Monday, with the Nasdaq and semiconductor shares leading a partial recovery from Friday’s sharp selloff, as investors hunted for bargains amid lingering optimism around artificial intelligence and relief that direct confrontations between Iran and Israel had paused, at least temporarily.

The S&P 500 rose 21.99 points, or 0.30%, to close at 7,405.73. The Nasdaq Composite gained 220.23 points, or 0.86%, to 25,929.66, while the Dow Jones Industrial Average slipped 80.77 points, or 0.16%, to 50,786.01. Technology stocks were the clear outperformers, with the S&P 500 technology sector advancing 1.5% and the Philadelphia Semiconductor Index surging 5.6%, clawing back some of the roughly $1 trillion in market value erased from chipmakers on Friday.

The rebound came after a volatile session in which stocks gave up much of their early gains. Apple shares eased late in the day and finished 1.9% lower, even as the company unveiled significant AI upgrades to Siri at its Worldwide Developers Conference in Cupertino. Investors appeared to adopt a “sell-the-news” stance after months of anticipation around Apple’s AI progress.

Intel jumped 11.2% after The Information reported that Google’s parent Alphabet had placed an order for more than 3 million tensor processing units in 2028. Broadcom rose 2.8% following last week’s results, while Marvell Technology surged 9.6% ahead of its inclusion in the S&P 500 on June 22. Eli Lilly gained 1.6% after trial results showed its next-generation obesity drug, retatrutide, reduced sleep apnea severity in addition to promoting weight loss and easing knee pain.

Rick Meckler, partner at Cherry Lane Investments, described the session as classic bargain hunting.

“Today looks like a day where investors are doing a little bit of bargain hunting off the big tech selloff. What normally happens after that is you get analysts coming in and reiterating buys,” he said.

He added a note of caution about the broader environment: “This market has been priced for quite a while for perfection, and these are certainly imperfect times. In that environment, you are going to see some back-and-forth, and some fear of prices having gone too far.”

Geopolitical Relief Provides Tailwind Amid Mixed Sector Performance

Markets also drew some comfort from news that Iran and Israel had halted direct attacks on each other following an appeal from President Donald Trump to “stop shooting.” The exchanges over the previous 24 hours marked the most intense confrontation since the April ceasefire. While tensions remain high and uncertainty persists around the wider U.S.-Iran conflict and the Strait of Hormuz, the pause helped reduce immediate risk premiums.

Declining issues slightly outnumbered advancers by a 1.01-to-1 ratio on the New York Stock Exchange, while advancing issues led on the Nasdaq by a 1.28-to-1 ratio. The S&P 500 recorded 13 new 52-week highs and 7 new lows, while the Nasdaq posted 105 new highs and 164 new lows. Volume on U.S. exchanges totaled 19.50 billion shares, below the recent 20-day average of roughly 20.3 billion.

The session highlighted the market’s continued sensitivity to both AI enthusiasm and macroeconomic signals. Friday’s stronger-than-expected May jobs report had fueled concerns about persistent inflation and potential Federal Reserve rate hikes under new Chair Kevin Warsh, triggering the broad selloff. Monday’s partial recovery suggests investors are still willing to buy dips in high-quality tech names, particularly in semiconductors, despite the elevated valuations and external risks.

Bruce Zaro, managing director at Granite Wealth Management, offered a perspective on Apple’s reaction.

“Perception has been for quite some time that Apple had been behind the curve as far as their AI offerings. That’s why the stock widely underperformed many of the other big techs for some time until recently,” he said.

SpaceX’s upcoming IPO, expected to be one of the largest in history, is also looming as a potential test of market appetite for mega-cap tech listings. Any signs of overexuberance or hesitation could influence sentiment across the broader technology sector.

Overall, analysts see Monday’s trading as a reflection of a market still grappling with high expectations. While AI-related optimism continues to underpin gains in semiconductors and growth stocks, external factors, from geopolitical developments in the Middle East to domestic inflation concerns, are introducing meaningful volatility. The rebound in chips suggests investors remain constructive on the long-term AI thesis, but the session also served as a reminder that the path higher will likely include periodic pullbacks as reality checks emerge.

With the Fed’s next policy meeting approaching and ongoing uncertainty around energy prices and global growth, investors will continue to weigh the balance between technological promise and macroeconomic risks. However, the willingness to buy dips in leading names is seen as an indication that confidence in the AI-driven growth story remains intact for now, even if perfection is no longer being fully priced in.

GSK to Acquire U.S. Biotech Firm Nuvalent for $10.6bn in Largest Pharma Deal in a Decade

0

GSK has agreed to acquire U.S. biotech firm Nuvalent in a $10.6 billion all-cash transaction, marking its biggest acquisition in more than ten years and a decisive push to strengthen its oncology portfolio, particularly in lung cancer treatments.

The deal, confirmed in a filing on Tuesday and first reported by the Financial Times, values Nuvalent at about $124 per share, a 40% premium to its previous closing price. It represents the second-largest acquisition in GSK’s corporate history, trailing only its 2014 asset swap with Novartis that reshaped its vaccines business.

The transaction marks a shift under new chief executive Luke Miels, who has moved away from the company’s recent preference for smaller, incremental acquisitions toward larger, pipeline-defining deals aimed at restoring long-term revenue growth.

With this deal, the oncology pipeline appears to become central to GSK’s strategy. At the core of the acquisition is Nuvalent’s experimental lung cancer portfolio, which GSK views as a platform for expanding its oncology franchise.

Nuvalent’s lead candidate, neladalkib, is currently under review by the U.S. Food and Drug Administration, with a decision expected by November 27. The therapy targets specific genetic mutations associated with non-small cell lung cancer, one of the largest oncology markets globally.

The company also has zidesamtinib under regulatory review, another targeted therapy aimed at ROS1-positive non-small cell lung cancer patients.

GSK has positioned the acquisition as a near-term revenue catalyst as well as a longer-term growth engine. The company expects the deal to begin contributing to revenue growth from 2027, with Improvements in profit contribution also expected from that year onward. Importantly, GSK has maintained its 2026 guidance for core operating profit and earnings-per-share growth, signaling that integration costs are expected to remain contained in the near term.

Industry Pressure From Patent Cliffs Drives Consolidation

The acquisition comes amid a broader wave of pharmaceutical dealmaking, as large drugmakers race to replace revenue streams threatened by expiring drug patents and slowing growth in legacy franchises.

Global biotech and pharmaceutical deal value has surged in 2026, with transactions reaching $106 billion across more than 200 deals, according to PitchBook data. The sector is on track for its strongest year since the pre-pandemic peak, driven by a combination of investor optimism, improved financing conditions, and intensified competition for late-stage drug assets.

Lung cancer remains one of the most lucrative therapeutic areas in oncology due to its high prevalence, complex biology, and continued demand for targeted therapies. That has made it a focal point for pharmaceutical companies seeking to secure differentiated assets with regulatory traction.

The deal also reflects a recalibration of GSK’s capital allocation strategy. Under previous guidance, the company had emphasized smaller transactions in the £2 billion to £4 billion range. Miels had previously described attractive opportunities in that range as “hiding in plain sight,” signaling a cautious approach to large-scale mergers.

The Nuvalent acquisition suggests a shift toward more aggressive portfolio rebuilding, particularly in high-value therapeutic categories such as oncology and immunology. Nuvalent itself has emerged as a high-profile clinical-stage biotech, with investor attention driven by its targeted approach to genetically defined cancers. Analysts have estimated that its lead therapies could generate combined annual revenues of roughly $823 million by 2029 if approved and successfully commercialized.

The transaction adds to a broader consolidation in the biotech sector, where large pharmaceutical firms are increasingly absorbing mid-sized innovation companies rather than developing late-stage drug candidates in-house. Rising research costs, longer development timelines, and regulatory uncertainty have pushed big pharma toward external innovation pipelines.

At the same time, improved capital market conditions have made biotech assets more expensive, intensifying competition among buyers.

The deal is thus both defensive and offensive for GSK: it mitigates pipeline risk while positioning the company in a competitive oncology segment where rival pharmaceutical groups are also expanding aggressively. The integration is expected to give GSK a more immediate foothold in precision oncology and potentially reshape its long-term revenue profile.

AI Trade Roars Back Across Asia as Chip Stocks Rally, but IPO Wave Raises Questions About Investor Appetite

0

Artificial intelligence-linked technology stocks staged a strong rebound across Asia on Tuesday, mirroring gains on Wall Street as investors returned to semiconductor and AI infrastructure plays after a sharp bout of profit-taking that rattled global technology markets last week.

The rally was led by South Korean chipmakers, underscoring continued investor conviction that demand for AI computing power remains robust even as concerns grow about valuations, capital spending, and an unprecedented wave of upcoming technology listings.

Shares of SK Hynix jumped 6.44%, while Samsung Electronics gained 3.38%. Smaller AI-linked names also benefited, with Seoul Semiconductor surging more than 12%.

Japan’s semiconductor ecosystem also participated in the recovery. Tokyo Electron rose 5.65%, Advantest advanced 1.51%, and Renesas Electronics climbed 2.54%.

The gains followed a strong session in the United States, where semiconductor stocks helped lift the broader market. The Nasdaq Composite rose 0.86% while the S&P 500 gained 0.3%, recovering part of last week’s losses as investors reassessed the outlook for AI-related spending.

While chipmakers and infrastructure providers attracted fresh buying, shares of SoftBank Group fell another 2%, extending recent declines after a spectacular run driven by enthusiasm surrounding artificial intelligence investments.

AI spending remains the market’s dominant narrative. Demand for advanced memory chips, graphics processors, networking equipment, and data-center infrastructure continues to accelerate as major technology companies race to expand computing capacity.

Recent comments from Nvidia CEO Jensen Huang that memory shortages could persist for years have bolstered the view that supply remains tight across critical AI components. That outlook has particularly benefited companies such as SK Hynix, which has emerged as a major supplier of high-bandwidth memory chips used in advanced AI systems.

The rally also comes amid expectations that AI infrastructure spending by hyperscale cloud providers, startups, and governments could continue expanding well into the next decade.

Despite Tuesday’s recovery, investors remain cautious as markets approach one of the most consequential IPO events in recent history. SpaceX is expected to price its highly anticipated public offering this week, with trading scheduled to begin shortly afterward.

The offering has become a focal point for global equity markets because of its sheer scale and its symbolic importance to the AI investment boom.

The company’s listing is expected to test whether public markets can absorb a surge of capital-intensive AI offerings without undermining valuations across the broader technology sector.

Investor attention is also shifting toward what could become the largest fundraising cycle in technology history. OpenAI recently confirmed it had confidentially filed for an initial public offering, following a similar move by Anthropic.

Together with SpaceX, the three companies represent trillions of dollars in potential market value and could collectively seek hundreds of billions of dollars from investors over the coming years.

That prospect is creating both excitement and concern. First, the filings signal confidence that AI adoption will continue expanding rapidly across industries, including software development, finance, healthcare, legal services, and enterprise automation. Secondly, some market participants worry that the concentration of fundraising could begin to drain liquidity from other sectors.

Andrew Jackson of ORTUS Advisors noted that OpenAI’s filing could tighten capital availability, particularly if investors increasingly direct funds toward a handful of dominant AI companies at the expense of smaller growth firms.

However, the valuation debate remains unresolved.

The rebound in Asian technology stocks suggests investors are not yet ready to abandon the AI trade. However, the market remains divided over whether current valuations accurately reflect future earnings potential.

The debate has intensified following warnings from investors such as Michael Burry and Steve Eisman, who have questioned whether the enormous sums being invested in AI infrastructure will ultimately generate sufficient returns.

At the same time, executives, including Goldman Sachs CEO David Solomon, argue that abundant liquidity, strong corporate demand, and accelerating AI adoption suggest the cycle may still be in its relatively early stages.

For now, the market appears to be siding with growth. Tuesday’s rally across Asian semiconductor stocks indicates investors continue to view chipmakers as some of the clearest beneficiaries of the AI boom.

The more difficult test may come later when SpaceX begins trading.

What Nigerian Bettors Can Expect From a Modern Bookmaker Platform

0

Sports betting in Nigeria has never been more competitive. Platforms are no longer judged solely on football coverage — players now evaluate a casino betting site based on the depth of its markets, the quality of its mobile interface, bonus structure, and payout speed. Among the platforms gaining traction in the Nigerian market, Pin Up has built a reputation as a well-rounded option for bettors who want more than just pre-match football odds. Its integrated approach — combining sportsbook depth with online casino Nigeria content — makes it relevant for a wide range of Nigerian players in 2026. This article looks at what the sportsbook actually offers and why those features matter.

Sports Betting Options Available on Pin-Up

Football remains the foundation of any serious Nigerian bookmaker. Football accounts for 75–85% of all wagers in Nigeria, with the English Premier League, UEFA Champions League, and Nigerian Professional Football League driving the highest engagement nationally.

Pin-Up covers this demand thoroughly. For each football match, players can explore hundreds of bet types, including Match Winner, Over/Under Goals, Asian Handicaps, Both Teams to Score, Correct Score, and Player Props such as First Goalscorer. The Nigerian Professional Football League (NPFL) is also supported, which matters for bettors who follow domestic football and want Pinup betting options that reflect local competition, not just European leagues.

Sports Beyond Football

Pinup bet games extend well past football. The platform gives Nigerian players access to over 40 sports categories, covering both international competitions and local Nigerian leagues. The full list of covered sports includes:

  • Basketball — NBA, EuroLeague, and FIBA competitions with player-prop markets
  • Tennis — Grand Slams through to ATP and WTA tour events
  • Combat sports — boxing and MMA title fights
  • Virtual sports — available around the clock regardless of live fixture schedules

This breadth means that sports betting PinUp style is not limited to weekend football. Players can find markets on most days of the week across multiple disciplines, which keeps the platform relevant beyond the typical Saturday matchday.

Live Betting and In-Play Markets

One of the strongest Pinup bet betting features is the live section. Pin-Up Bet live runs fast and works well even during peak hours, with pre-match and real-time bets accessible instantly and no delay in updates for global matches and local leagues.

The Bet Builder feature allows custom combinations of up to 16 outcomes per bet on Football, Basketball, and Baseball matches, while Cash Out and Edit Bets give players control even after placement. For Nigerian bettors who engage with games on mobile, these tools add a meaningful layer of flexibility to the live betting experience.

Casino Betting Site Features Alongside the Sportsbook

Pin-Up is not purely a sportsbook. The platform integrates a full online casino Nigeria section, meaning players can move between sports betting options and casino games without leaving the app or creating a separate account.

Pin-Up bookmaker and casino features are integrated into one app, allowing seamless switching between game types — and according to Statista (2024), over 71% of Nigerian digital gamblers cite bonus programs as a top reason for staying loyal to a platform.

The casino component includes popular casino games such as online slots, crash games like Aviator, and live dealer tables. For players who want to play online casino Nigeria titles during downtime between fixtures, this means the platform functions as a complete real money casino Nigeria destination. The welcome bonus structure reflects this duality — new users can choose between a sports-focused offer or a casino bonus with free spins, depending on their preference.

Security, Licensing, and Payments

A trusted casino Nigeria operator must be transparent about its legal standing. Pin-Up Bet operates under the Curaçao Gaming Control Board licence (OGL/2024/580/0570), issued with indefinite validity and managed by Carletta N.V. Deposits and withdrawals are processed in Nigerian Naira, with a minimum deposit of ?100 and withdrawals completed within 24 hours. Fast payouts and NGN support remove two of the most common frustrations Nigerian players report with international betting platforms.

For Nigerian players evaluating their options in 2026, the combination of sports betting options — over 40 sports, in-depth football markets, live betting tools, and a Bet Builder — alongside an integrated casino gaming platform makes Pin-Up a strong candidate worth considering. The platform’s transparent licensing, local currency support, and competitive welcome offers round out a package designed to meet what today’s Nigerian bettor actually expects from a modern bookmaker.

Perplexity Confirms 2028 IPO as AI Listing Wave Tests Investor Appetite for Trillion-Dollar Valuations

0

Perplexity is pressing ahead with plans to go public in 2028, positioning itself as the next major artificial intelligence company likely to tap public markets after the highly anticipated listings of OpenAI, Anthropic, and SpaceX.

Speaking to CNBC, Perplexity CEO Aravind Srinivas said the company’s IPO plans remain unchanged regardless of how investors respond to the blockbuster offerings expected over the next two years.

“Agnostic of these two companies, we were planning for something in 2028 so that still remains the case,” Srinivas said.

His comments provide the clearest indication yet that Perplexity is preparing for a public market debut, even as investors grapple with questions about whether the AI sector’s soaring valuations can be sustained.

The AI industry is entering what could become the most significant wave of technology listings since the dot-com era, with SpaceX, Anthropic, and OpenAI all moving toward public markets. Together, those companies could add several trillion dollars in market capitalization to global equity markets, creating a crucial test of investor enthusiasm for AI-related assets.

SpaceX Seen as the First Major Test

While Perplexity’s IPO remains years away, Srinivas acknowledged that the market’s reception of upcoming AI and technology offerings will shape investor sentiment across the sector.

“I certainly think there will be ripple effects if they don’t go well, like there is no sugar coating on that. The SpaceX IPO this week will definitely be a leading indicator to how Anthropic or OpenAI will go out,” he said.

The statement reflects growing recognition across Silicon Valley that SpaceX’s public debut may serve as a barometer for risk appetite in an era defined by massive capital spending on artificial intelligence infrastructure.

Investors are closely watching whether public markets are willing to support the extraordinary valuations attached to the industry’s leading players. Anthropic was last valued at nearly $1 trillion in private markets, while OpenAI’s valuation has climbed to levels that place it among the world’s most valuable technology companies before even going public.

Despite those concerns, Srinivas remains optimistic.

“I think it’s important for the AI industry that these IPOs go well, and I actually think they will go well, because they’re doing well,” he said.

Why Frontier AI Companies Command Premium Valuations

The debate over AI valuations has intensified as companies spend hundreds of billions of dollars on chips, data centers, and research. Srinivas argued that companies such as OpenAI and Anthropic deserve their lofty valuations because they remain at the cutting edge of AI development.

“They are on the frontier,” he said.

However, he suggested that their valuations ultimately depend on maintaining a rapid pace of innovation.

“If for six months you don’t see a model capability advance from one of these two companies, then it’s a problem for them.”

Unlike traditional software companies, the valuations of AI developers are increasingly tied to the expectation that each new generation of models will deliver significant leaps in capability. Any prolonged slowdown could trigger investor concerns about whether the enormous investments flowing into AI are generating adequate returns.

For much of the past two years, enterprises raced to adopt generative AI tools with little scrutiny of costs. Now, companies are becoming more selective about where and how they deploy AI. OpenAI CEO Sam Altman recently highlighted rising concerns around AI spending, reportedly describing costs as a “huge issue” as businesses evaluate returns on their investments.

According to Srinivas, the next phase of AI adoption will be defined by efficiency rather than indiscriminate spending.

He pointed to a growing phenomenon known as “tokenmaxxing,” where employees maximize the usage of AI tools to demonstrate productivity. But he argued that businesses are becoming more sophisticated.

“People don’t want to just tokenmax, they really want to use whatever model is the best for that particular task,” he said.

That trend could benefit companies like Perplexity, whose platform can draw on multiple AI models and select the most appropriate one based on performance and cost considerations.

Rather than relying exclusively on expensive frontier models, Srinivas expects enterprises to increasingly mix cutting-edge systems with cheaper open-source alternatives.

“If there is an open source model that gets the job done 90% of the time, I’d probably use that if it’s 10 to 20 times cheaper than the frontier model,” he explained.

The shift toward cost-conscious deployment could reshape how enterprises allocate AI budgets over the coming years.

“The future is still awesome for frontier intelligence, but it’s not going to be mindless spending, as we saw in the last few months,” Srinivas said.

Overall, Perplexity’s planned 2028 IPO is seen as another indication of confidence that public markets will continue rewarding companies positioned at the center of the AI revolution. Investors are beginning to focus less on AI hype and more on tangible measures such as model performance, commercialization strategies, infrastructure costs, and long-term profitability.

For now, the immediate focus remains on SpaceX, followed by Anthropic and OpenAI. If those offerings succeed, they could unlock a new era of AI-driven public market activity and pave the way for companies such as Perplexity to follow.